Generate Investment Management Ltd Has $8.55 Million Stock Position in Cencora, Inc. (NYSE:COR)

Generate Investment Management Ltd cut its stake in Cencora, Inc. (NYSE:COR - Free Report) by 33.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,743 shares of the company's stock after selling 15,765 shares during the period. Generate Investment Management Ltd's holdings in Cencora were worth $8,549,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Net Worth Advisory Group increased its position in shares of Cencora by 1.4% during the 1st quarter. Net Worth Advisory Group now owns 2,645 shares of the company's stock valued at $736,000 after purchasing an additional 36 shares during the period. Whittier Trust Co. grew its holdings in Cencora by 0.6% during the fourth quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock worth $1,765,000 after acquiring an additional 44 shares during the period. Cullen Frost Bankers Inc. raised its position in Cencora by 1.1% in the fourth quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company's stock worth $1,003,000 after acquiring an additional 47 shares in the last quarter. Permanent Capital Management LP lifted its holdings in Cencora by 4.0% in the 1st quarter. Permanent Capital Management LP now owns 1,238 shares of the company's stock valued at $344,000 after acquiring an additional 48 shares during the last quarter. Finally, Exchange Traded Concepts LLC boosted its position in shares of Cencora by 4.5% during the 1st quarter. Exchange Traded Concepts LLC now owns 1,104 shares of the company's stock valued at $307,000 after purchasing an additional 48 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Insider Transactions at Cencora

In other news, CEO Robert P. Mauch sold 4,969 shares of the stock in a transaction on Monday, April 21st. The shares were sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the transaction, the chief executive officer now owns 47,582 shares in the company, valued at $13,766,900.06. This represents a 9.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction on Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the completion of the sale, the chairman now directly owns 315,913 shares of the company's stock, valued at approximately $89,027,442.53. The trade was a 4.41% decrease in their position. The disclosure for this sale can be found here. Insiders sold 34,127 shares of company stock valued at $9,812,296 in the last three months. Corporate insiders own 10.80% of the company's stock.

Cencora Stock Up 1.5%

NYSE COR traded up $4.38 during trading on Thursday, reaching $296.70. 1,645,496 shares of the company's stock were exchanged, compared to its average volume of 1,518,180. The firm has a market capitalization of $57.51 billion, a PE ratio of 34.42, a P/E/G ratio of 1.45 and a beta of 0.58. Cencora, Inc. has a fifty-two week low of $218.65 and a fifty-two week high of $309.35. The company has a current ratio of 0.87, a quick ratio of 0.52 and a debt-to-equity ratio of 6.01. The company's fifty day simple moving average is $289.70 and its 200-day simple moving average is $264.56.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The firm had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. During the same period in the previous year, the firm posted $3.80 earnings per share. The firm's revenue was up 10.3% on a year-over-year basis. Sell-side analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were given a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.74%. The ex-dividend date was Friday, May 16th. Cencora's payout ratio is currently 25.52%.

Wall Street Analyst Weigh In

Several analysts recently commented on COR shares. Robert W. Baird increased their target price on shares of Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Wells Fargo & Company raised Cencora from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $274.00 to $337.00 in a report on Tuesday, June 3rd. Wall Street Zen upgraded Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. UBS Group boosted their target price on Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Finally, Citigroup increased their price target on Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $306.91.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.